Kymera
proprietary platform | Kymera
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
88 of 105
Related slides by other companies
BenevolentAI
Investor Conference
January 2023
ben results and progress to date target identification chemistry clinical development novel target for rapid and lead developing responder and progression | BenevolentAI
Immatics
Investor Presentation
November 2023
unique capability identification of the most relevant target | Immatics
BenevolentAI
Results
March 2023
ben results and progress to date target identification chemistry clinical development novel target for rapid and lead developing responder and progression discovered using benevolent tools molecular design tools enabled rapid and lead has zero linkage to in all available literature experimentally validated in colon samples from patients refractory to soc treatment candidate nominated in novel potent selective peripherally restricted inhibitor with low dose prediction we will develop responder and progression adding molecular these will inform our trial design patient selection and further target cation in delivered drug candidate within years from initiation augmenting a further loop of iteration on an enriched graph | BenevolentAI
Other recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io